Research at CRE REDUCE aims to:

  1. Describe the effect of different infection pathologies on plasma & infection site antibiotic pharmacokinetics
  2. Define doses for patients that prevent the development of resistance
  3. Test patient tolerability & capacity to suppress the emergence of antibiotic resistance of novel doses in clinical trials & measure cost-effectiveness 
  4. Trials to measure the effect of PK/PD interventions on clinical outcomes
  5. Improve the patient experience for novel treatment of infections through consumer participation in CRE research
  6. Support development of new antibiotic dosing guidelines for treatment of difficult infections through publication through Australian & international societies